In a study of 63 patients with SCLC, 52 (83%) patient tumor samples were found to be positive for DLL3 expression by immunohistochemistry (IHC), and 20 (32%) showed high expression of DLL3 (positive in at least 50% of cancer cells) [26]. The gene discussed is DLL3; the disease is cancer.